The Experts below are selected from a list of 73650 Experts worldwide ranked by ideXlab platform
Antonio Gasbarrini - One of the best experts on this subject based on the ideXlab platform.
-
levofloxacin based triple therapy in first line treatment for Helicobacter Pylori eradication
The American Journal of Gastroenterology, 2006Co-Authors: E C Nista, Giovanni Gasbarrini, Marcello Candelli, M A Zocco, Filippo Cremonini, Veronica Ojetti, R Finizio, Cristiano Spada, Giovanni Cammarota, Antonio GasbarriniAbstract:Levofloxacin-Based Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
-
regression of autoimmune thrombocytopenia after eradication of Helicobacter Pylori
The Lancet, 1998Co-Authors: Antonio Gasbarrini, Raffaele Tartaglione, Paolo Pola, Francesco Franceschi, Raffaele Landolfi, Giovanni GasbarriniAbstract:1 Negrini R, Savio A, Poiesi C, et al. Antigenic minicry between H Pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastreonterology 1996; 111: 655–65. 2 Ko GH, Part HB, Shin MK, et al. Monoclonal antibodies against Helicobacter Pylori cross-react with human tissue. Helicobacter 1997; 4: 210–15. 3 Nagachima R, Maeda K, Yuda F, Kudo K, Saitoh M, Takahashi T. Helicobacter Pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch 1997; 431: 235–39. 4 Machet L, Vaillant L, Machet MC, Buchler M, Lorette G. SchonleinHenoch purpura associated with gastric Helicobacter Pylori infection. Dermatology 1997; 194: 86. 5 Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103: 114–20.
Paul Moayyedi - One of the best experts on this subject based on the ideXlab platform.
-
Helicobacter Pylori infection in functional dyspepsia
Nature Reviews Gastroenterology & Hepatology, 2013Co-Authors: Hidekazu Suzuki, Paul MoayyediAbstract:Helicobacter Pylori infection is one likely cause of functional dyspepsia. Here, the authors discuss the clinical evidence in relation to H. Pylori eradication in patients with functional dyspepsia if they test positive for this bacterium.
-
eradication therapy in Helicobacter Pylori positive peptic ulcer disease systematic review and economic analysis
The American Journal of Gastroenterology, 2004Co-Authors: Alexander C. Ford, Brendan Delaney, David Forman, Paul MoayyediAbstract:Eradication Therapy in Helicobacter Pylori Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis
Zhe Shen - One of the best experts on this subject based on the ideXlab platform.
-
Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis a systematic review and meta analysis
Helicobacter, 2018Co-Authors: Li Cen, Jiaqi Pan, Boyan Zhou, Weixing Chen, Zhe ShenAbstract:Background Helicobacter Pylori is coexisted with various diseases, including chronic gastritis, ulcer, and gastric cancer. Besides, chronic cholecystitis and cholelithiasis are extremely widespread over the world, which are considered as high health-care cost burdens of digestive diseases. Epidemiologic evidence on Helicobacter Pylori infection in gallbladder increasing the risk of biliary diseases has been contradictory. Aim Conduct a meta-analysis of overall studies and investigate an association between Helicobacter Pylori infection of the gallbladder with chronic cholecystitis/cholelithiasis. Methods We used PubMed, EMBASE, and Cochrane library databases to identify all published studies before August 2017. Pooled odds ratios (OR) and corresponding 95% confidence intervals (CIs) were obtained using the random effects model. Heterogeneity, sensitivity, and stratified analyses were also performed. Results Eighteen studies involving 1544 participants and 1061 biliary cases with chronic cholecystitis/cholelithiasis were included. Helicobacter Pylori infection of the gallbladder was significantly associated with an increased risk of chronic cholecystitis and cholecystitis (OR = 3.022; 95% CI, 1.897-4.815; I2 = 20.1%). In addition, country-based subgroup analysis also showed a positive association between Helicobacter Pylori positivity and chronic cholecystitis/cholelithiasis risk. The ORs (95% CIs) for Asian and non-Asian region studies were 3.75 (1.83-7.71) and 2.25 (1.29-3.89), respectively. Conclusion This meta-analysis suggests that infection of the gallbladder with Helicobacter Pylori is closely related to an increased risk of chronic cholecystitis and cholelithiasis.
Johansson Anders - One of the best experts on this subject based on the ideXlab platform.
-
Impact of a Fermented High-Fiber Rye Diet on Helicobacter Pylori and Cardio-Metabolic Risk Factors: A Randomized Controlled Trial Among Helicobacter Pylori-Positive Chinese Adults
'Frontiers Media SA', 2021Co-Authors: Xue Kun, Liu Yuwei, Nøhr Iversen Kia, Mazidi Mohsen, Qu Zheng, Dong Chenglin, Jin Tayi, Hallmans Göran, Per Åman, Johansson AndersAbstract:Background: High dietary fiber intake has been associated with reduced risk of Helicobacter Pylori infection and co-morbidities such as gastric cancer but also with reduced risk of cardiovascular disease. It has been suggested that fermented rye could affect Helicobacter Pylori bacterial load and that high- fiber rye may be superior to wheat for improvement of several cardiometabolic risk factors, but few long-term interventions with high fiber rye foods have been conducted. Objective: To examine the effect of high-fiber wholegrain rye foods with added fermented rye bran vs. refined wheat on Helicobacter Pylori infection and cardiometabolic risk markers in a Chinese population with a low habitual consumption of high fiber cereal foods. Design: A parallel dietary intervention was set up and 182 normal- or overweight men and women were randomized to consume wholegrain rye products containing fermented rye bran (FRB) or refined wheat (RW) for 12 weeks. Anthropometric measurements, fasting blood sample collection and 13C-urea breath test (13C-UBT) were performed at baseline and after 6 and 12 weeks of intervention as well as 12 weeks after the end of the intervention. Results: No difference between diets on Helicobacter Pylori bacterial load measured by 13C-UBT breath test or in virulence factors of Helicobacter Pylori in blood samples were found. Low density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive protein (hs-CRP) were significantly lower in the FRB group, compared to the RW group after 12 weeks of intervention. The intervention diets did not affect markers of glucose metabolism or insulin sensitivity. Conclusions: While the results of the present study did not support any effect of FRB on Helicobacter Pylori bacterial load, beneficial effects on LDL-C and hs-CRP were clearly shown. This suggest that consumption of high fiber rye foods instead of refined wheat could be one strategy for primary prevention of cardiovascular disease
-
Impact of a Fermented High-Fiber Rye Diet on Helicobacter Pylori and Cardio-Metabolic Risk Factors : A Randomized Controlled Trial Among Helicobacter Pylori-Positive Chinese Adults
'Frontiers Media SA', 2021Co-Authors: Xue Kun, Liu Yuwei, Nøhr Iversen Kia, Mazidi Mohsen, Qu Zheng, Dong Chenglin, Jin Tayi, Hallmans Göran, Per Åman, Johansson AndersAbstract:Background: High dietary fiber intake has been associated with reduced risk of Helicobacter Pylori infection and co-morbidities such as gastric cancer but also with reduced risk of cardiovascular disease. It has been suggested that fermented rye could affect Helicobacter Pylori bacterial load and that high- fiber rye may be superior to wheat for improvement of several cardiometabolic risk factors, but few long-term interventions with high fiber rye foods have been conducted. Objective: To examine the effect of high-fiber wholegrain rye foods with added fermented rye bran vs. refined wheat on Helicobacter Pylori infection and cardiometabolic risk markers in a Chinese population with a low habitual consumption of high fiber cereal foods. Design: A parallel dietary intervention was set up and 182 normal- or overweight men and women were randomized to consume wholegrain rye products containing fermented rye bran (FRB) or refined wheat (RW) for 12 weeks. Anthropometric measurements, fasting blood sample collection and 13C-urea breath test (13C-UBT) were performed at baseline and after 6 and 12 weeks of intervention as well as 12 weeks after the end of the intervention. Results: No difference between diets on Helicobacter Pylori bacterial load measured by 13C-UBT breath test or in virulence factors of Helicobacter Pylori in blood samples were found. Low density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive protein (hs-CRP) were significantly lower in the FRB group, compared to the RW group after 12 weeks of intervention. The intervention diets did not affect markers of glucose metabolism or insulin sensitivity. Conclusions: While the results of the present study did not support any effect of FRB on Helicobacter Pylori bacterial load, beneficial effects on LDL-C and hs-CRP were clearly shown. This suggest that consumption of high fiber rye foods instead of refined wheat could be one strategy for primary prevention of cardiovascular disease
Tadayoshi Okimoto - One of the best experts on this subject based on the ideXlab platform.
-
Influence of acotiamide on 13 C-urea breath test for Helicobacter Pylori diagnosis
Journal of clinical biochemistry and nutrition, 2020Co-Authors: Kazuhiro Mizukami, Makoto Katsuta, Kazuhisa Okamoto, Kensuke Fukuda, Ryo Ogawa, Yoshinari Kawahara, Yuka Hirashita, Yuto Sato, Masahide Fukuda, Tadayoshi OkimotoAbstract:The Helicobacter Pylori infection and functional dyspepsia are often coexisted. The effect of acotiamide, a drug for functional dyspepsia, on the result of Helicobacter Pylori diagnosis has yet to be studied. We evaluated the influence of acotiamide on the results of Helicobacter Pylori diagnosis in the 13C-urea breath test. Twenty patients with Helicobacter Pylori-positive functional dyspepsia were treated with 100 mg of acotiamide three times a day for two weeks. Changes in 13C-urea breath test were investigated before and after administration, and two weeks after administration as the follow-up period. The 13C-urea breath test and the medical questionnaire of modified frequency scale for the symptoms of gastroesophageal reflux disease were conducted at every period. Nineteen patients were included for analysis. No patients showed negative in 13C-urea breath test at Weeks 2 and 4. On the symptom scale, dyspepsia and total scores decreased from Week 0 to Week 2 and increased from Week 2 to Week 4, and the improvement rates of the dyspepsia score at Week 2 was 63%. In conclusion, we confirmed that acotiamide is unlikely to influence the result of 13C-urea breath test and it may improve the symptoms of functional dyspepsia during Helicobacter Pylori eradication treatment.